Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Schneerson; Rachel
Address:
Bethesda, MD
No. of patents:
12
Patents:












Patent Number Title Of Patent Date Issued
8202520 Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine June 19, 2012
This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in
8044189 Bacillus anthracis protective antigen nucleic acid sequences October 25, 2011
The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, in
7803386 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli September 28, 2010
Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-.gamma.-glutamic acid (.gamma.PGA) polypeptide of B. anthracis, or of another Bacillus that expresses a .gamma.PGA p
7763451 Methods for preparing Bacillus anthracis protective antigen for use in vaccines July 27, 2010
The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, in
7754227 Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine July 13, 2010
This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in
7666846 Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi February 23, 2010
Unique compounds that can be used for inducing an immune response to Borrelia burgdorferi in a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for preventing or treating Lyme disease in a subject.
7625736 Methods for preparing immunogenic conjugates December 1, 2009
Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier;
7422755 Antimultiorganism glycoconjugate vaccine September 9, 2008
The present invention relates, e.g., to a glycoconjugate composition comprising one or more polysaccharide types from a cell wall polysaccharide preparation from B. pumilus Sh 18, or variants thereof. Also disclosed are antibodies generated against the glycoconjugates, and methods of
7261900 Recombinant modified Bacillus anthracis protective antigen for use in vaccines August 28, 2007
The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these
6632437 Immunogenic polysaccharide-protein conjugates containing poly .alpha.(2.fwdarw.8), .alpha.(2.fwd October 14, 2003
The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a poly
5445817 Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines August 29, 1995
A medically important and useful conjugate comprising pertussis toxin (PT), or another antigen having similar physico-chemical properties, as the carrier protein component, coupled to a neutral or non-charged saccharide, particularly, the capsular polysaccharide of Streptococcus pneumoni
5204098 Polysaccharide-protein conjugates April 20, 1993
Vi capsular polysaccharides conjugated to toxin-dependent proteins can be used to enhance antibody response and to convert T-dependent properties to the Vi capsular polysaccharide. A heterobifunctional crosslinking agent can be used to bind thiol derivatives of the Vi capsular polysaccha










 
 
  Recently Added Patents
LED light
Wireless device and communication control method
TC-83-derived alphavirus vectors, particles and methods
System and method for routing streaming data requests
Nitride semiconductor laser device
Systems and methods of using dynamic data for wear leveling in solid-state devices
Circuitry testing module and circuitry testing device
  Randomly Featured Patents
Image recording system and method
Automatic transmission
Kickstand support pad
Incorporation of carbon in silicon/silicon germanium epitaxial layer to enhance yield for Si-Ge bipolar technology
Exothermic two-stage process for catalytic oxidation of hydrogen chloride
Wavelength locked integrated optical source structure using multiple microcavity
Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
Gaming device multilateration location
Programmed controller for a remotely-controlled battery-powered window covering
Electrochemical double layer capacitor having carbon powder electrodes